New fronts emerge in the influenza cytokine storm

Seminars in Immunopathology

Volumn 39, Issue 5, 2017, Pages 541-550

  Guo, Xi zhi J ^a,b   Thomas, Paul G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; CYTOKINE;

CYTOKINE STORM; HUMAN; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CYTOLOGY; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INFLUENZA A VIRUS; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANIMALS; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLUENZA A VIRUS; INFLUENZA, HUMAN;

EID: 85019731124     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-017-0636-y     Document Type: Review

References (116)

1. Thompson WW, Shay DK, Weintraub E et al (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340. doi:10.1001/jama.292.11.1333
2. Dash P, Thomas PG (2014) Host Detection and the Stealthy Phenotype in Influenza Virus Infection. In: Oldstone MBA, Compans RW (eds) Influenza Pathog. Control - Vol. II. Springer International Publishing, pp 121–147
3. Yokota S (2003) Influenza-associated encephalopathy--pathophysiology and disease mechanisms. Nihon Rinsho Jpn J Clin Med 61:1953–1958
4. Clark IA (2007) The advent of the cytokine storm. Immunol Cell Biol 85:271–273. doi:10.1038/sj.icb.7100062
5. Tisoncik JR, Korth MJ, Simmons CP et al (2012) Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76:16–32. doi:10.1128/MMBR.05015-11
6. Liu Q, Zhou Y, Yang Z (2016) The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 13:3–10. doi:10.1038/cmi.2015.74
7. Teijaro JR (2014) The Role of Cytokine Responses During Influenza Virus Pathogenesis and Potential Therapeutic Options. In: Oldstone MBA, Compans RW (eds) Influenza Pathog. Control - Vol. II. Springer International Publishing, pp 3–22
8. D’Elia RV, Harrison K, Oyston PC et al (2013) Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol 20:319–327. doi:10.1128/CVI.00636-12
9. Kato H, Sato S, Yoneyama M et al (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19–28. doi:10.1016/j.immuni.2005.04.010
10. Teijaro JR, Walsh KB, Cahalan S et al (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980–991. doi:10.1016/j.cell.2011.08.015
11. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258–267
12. McNab F, Mayer-Barber K, Sher A et al (2015) Type I interferons in infectious disease. Nat Rev Immunol 15:87–103. doi:10.1038/nri3787
13. Iwasaki A, Pillai PS (2014) Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328. doi:10.1038/nri3665
14. Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36–49. doi:10.1038/nri3581
15. Wack A, Terczyńska-Dyla E, Hartmann R (2015) Guarding the frontiers: the biology of type III interferons. Nat Immunol 16:802–809. doi:10.1038/ni.3212
16. Sadler AJ, Williams BRG (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559–568. doi:10.1038/nri2314
17. Muller U, Steinhoff U, Reis LF et al (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918–1921. doi:10.1126/science.8009221
18. Davidson S, Crotta S, McCabe TM, Wack A (2014) Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun 5:3864. doi:10.1038/ncomms4864
19. Rosenberger CM, Podyminogin RL, Askovich PS et al (2014) Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell model. J Gen Virol 95:350–362. doi:10.1099/vir.0.058438-0
20. Kohlmeier JE, Cookenham T, Roberts AD et al (2010) Type I interferons regulate Cytolytic activity of memory CD8+ T cells in the lung airways during respiratory virus challenge. Immunity 33:96–105. doi:10.1016/j.immuni.2010.06.016
21. Koerner I, Kochs G, Kalinke U et al (2007) Protective role of Beta interferon in host defense against influenza a virus. J Virol 81:2025–2030. doi:10.1128/JVI.01718-06
22. Durbin JE, Fernandez-Sesma A, Lee C-K et al (2000) Type I IFN modulates innate and specific antiviral immunity. J Immunol 164:4220–4228. doi:10.4049/jimmunol.164.8.4220
23. Lazear HM, Nice TJ, Diamond MS (2015) Interferon-λ: immune functions at barrier surfaces and beyond. Immunity 43:15–28. doi:10.1016/j.immuni.2015.07.001
24. Jewell NA, Cline T, Mertz SE et al (2010) Lambda interferon is the predominant interferon induced by influenza a virus infection in vivo. J Virol 84:11515–11522. doi:10.1128/JVI.01703-09
25. Mordstein M, Kochs G, Dumoutier L et al (2008) Interferon-λ contributes to innate immunity of mice against influenza a virus but not against Hepatotropic viruses. PLoS Pathog 4:e1000151. doi:10.1371/journal.ppat.1000151
26. Mordstein M, Neugebauer E, Ditt V et al (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84:5670–5677. doi:10.1128/JVI.00272-10
27. Thomas PG, Dash P, Aldridge JR Jr et al (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza a virus via the regulation of caspase-1. Immunity 30:566–575. doi:10.1016/j.immuni.2009.02.006
28. Allen IC, Scull MA, Moore CB et al (2009) The NLRP3 Inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA. Immunity 30:556–565. doi:10.1016/j.immuni.2009.02.005
29. Thapa RJ, Ingram JP, Ragan KB et al (2016) DAI senses influenza a virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe 20:674–681. doi:10.1016/j.chom.2016.09.014
30. Kuriakose T, Man SM, Malireddi RKS et al (2016) ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci Immunol 1:aag2045–aag2045. doi:10.1126/sciimmunol.aag2045
31. Schmitz N, Kurrer M, Bachmann MF, Kopf M (2005) Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 79:6441–6448. doi:10.1128/JVI.79.10.6441-6448.2005
32. Pang IK, Ichinohe T, Iwasaki A (2013) IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8+ T cell responses to influenza a virus. Nat Immunol 14:246–253. doi:10.1038/ni.2514
33. Ichinohe T, Lee HK, Ogura Y et al (2009) Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206:79–87. doi:10.1084/jem.20081667
34. Tate MD, Ong JDH, Dowling JK et al (2016) Reassessing the role of the NLRP3 inflammasome during pathogenic influenza a virus infection via temporal inhibition. Sci Rep 6:27912. doi:10.1038/srep27912
35. Liu B, Mori I, Hossain MJ et al (2004) Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 85:423–428. doi:10.1099/vir.0.19596-0
36. Denton AE, Doherty PC, Turner SJ, La Gruta NL (2007) IL-18, but not IL-12, is required for optimal cytokine production by influenza virus-specific CD8+ T cells. Eur J Immunol 37:368–375. doi:10.1002/eji.200636766
37. Van Der Sluijs KF, Van Elden LJR, Arens R et al (2005) Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza a virus. Immunology 114:112–120. doi:10.1111/j.1365-2567.2004.02000.x
38. Lupfer C, Thomas PG, Anand PK et al (2013) Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection. Nat Immunol 14:480–488. doi:10.1038/ni.2563
39. Sareneva T, Matikainen S, Kurimoto M, Julkunen I (1998) Influenza a virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ Gene expression in human T cells. J Immunol 160:6032–6038
40. Chao Y, Kaliaperumal N, Chretien A-S et al (2014) Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. J Leukoc Biol 96:1037–1046. doi:10.1189/jlb.2A0813-465RR
41. Aldridge JR, Moseley CE, Boltz DA et al (2009) TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci 106:5306–5311. doi:10.1073/pnas.0900655106
42. Veckman V, Österlund P, Fagerlund R et al (2006) TNF-α and IFN-α enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology 345:96–104. doi:10.1016/j.virol.2005.09.043
43. Hufford MM, Kim TS, Sun J, Braciale TJ (2014) The Effector T Cell Response to Influenza Infection. In: Oldstone MBA, Compans RW (eds) Influenza Pathog. Control - Vol. II. Springer International Publishing, pp 423–455
44. Peiris JSM, Cheung CY, Leung CYH, Nicholls JM (2009) Innate immune responses to influenza a H5N1: friend or foe? Trends Immunol 30:574–584. doi:10.1016/j.it.2009.09.004
45. Cheung C, Poon L, Lau A et al (2002) Induction of proinflammatory cytokines in human macrophages by influenza a (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360:1831–1837. doi:10.1016/S0140-6736(02)11772-7
46. Chan M, Cheung C, Chui W et al (2005) Proinflammatory cytokine responses induced by influenza a (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6:135. doi:10.1186/1465-9921-6-135
47. Szretter KJ, Gangappa S, Lu X et al (2007) Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 81:2736–2744. doi:10.1128/JVI.02336-06
48. Perrone LA, Szretter KJ, Katz JM et al (2010) Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 202:1161–1170. doi:10.1086/656365
49. Hussell T, Pennycook A, Openshaw PJM (2001) Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 31:2566–2573. doi:10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
50. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457. doi:10.1038/ni.3153
51. Jones SA, Scheller J, Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121:3375–3383. doi:10.1172/JCI57158
52. Atreya R, Neurath MF (2005) Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 28:187–195. doi:10.1385/CRIAI:28:3:187
53. Rincon M (2012) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 33:571–577. doi:10.1016/j.it.2012.07.003
54. Oshansky CM, Gartland AJ, Wong S-S et al (2013) Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am J Respir Crit Care Med 189:449–462. doi:10.1164/rccm.201309-1616OC
55. Kaiser L, Fritz RS, Straus SE et al (2001) Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 64:262–268. doi:10.1002/jmv.1045
56. Hagau N, Slavcovici A, Gonganau DN et al (2010) Clinical aspects and cytokine response in severe H1N1 influenza a virus infection. Crit Care 14:R203. doi:10.1186/cc9324
57. Dienz O, Rud JG, Eaton SM et al (2012) Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5:258–266. doi:10.1038/mi.2012.2
58. Lauder SN, Jones E, Smart K et al (2013) Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol 43:2613–2625. doi:10.1002/eji.201243018
59. Longhi MP, Wright K, Lauder SN et al (2008) Interleukin-6 is crucial for recall of influenza-specific memory CD4+ T cells. PLoS Pathog 4:e1000006. doi:10.1371/journal.ppat.1000006
60. Molofsky AB, Savage AK, Locksley RM (2015) Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 42:1005–1019. doi:10.1016/j.immuni.2015.06.006
61. Liew FY, Girard J-P, Turnquist HR (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16:676–689. doi:10.1038/nri.2016.95
62. Martin NT, Martin MU (2016) Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 17:122–131. doi:10.1038/ni.3370
63. Kakkar R, Lee RT (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7:827–840. doi:10.1038/nrd2660
64. Cayrol C, Girard J-P (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31:31–37. doi:10.1016/j.coi.2014.09.004
65. Peine M, Marek RM, Löhning M (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333. doi:10.1016/j.it.2016.03.007
66. Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490. doi:10.1016/j.immuni.2005.09.015
67. Carriere V, Roussel L, Ortega N et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci 104:282–287. doi:10.1073/pnas.0606854104
68. Kearley J, Silver JS, Sanden C et al (2015) Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42:566–579. doi:10.1016/j.immuni.2015.02.011
69. Bonilla WV, Fröhlich A, Senn K et al (2012) The Alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 335:984–989. doi:10.1126/science.1215418
70. Le Goffic R, Arshad MI, Rauch M et al (2011) Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol 45:1125–1132. doi:10.1165/rcmb.2010-0516OC
71. Monticelli LA, Sonnenberg GF, Abt MC et al (2011) Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12:1045–1054. doi:10.1038/ni.2131
72. Arpaia N, Green JA, Moltedo B et al (2015) A distinct function of regulatory T cells in tissue protection. Cell 162:1078–1089. doi:10.1016/j.cell.2015.08.021
73. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386. doi:10.1038/nri1604
74. Billiau A, Matthys P (2009) Interferon-γ: a historical perspective. Cytokine Growth Factor Rev 20:97–113. doi:10.1016/j.cytogfr.2009.02.004
75. Turner SJ, Olivas E, Gutierrez A et al (2007) Disregulated influenza a virus-specific CD8+ T cell homeostasis in the absence of IFN-γ signaling. J Immunol 178:7616–7622. doi:10.4049/jimmunol.178.12.7616
76. Graham MB, Dalton DK, Giltinan D et al (1993) Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J Exp Med 178:1725–1732. doi:10.1084/jem.178.5.1725
77. Baumgarth N, Kelso A (1996) In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J Virol 70:4411–4418
78. Karupiah G, Chen J-H, Mahalingam S et al (1998) Rapid interferon γ–dependent clearance of influenza a virus and protection from consolidating pneumonitis in nitric oxide synthase 2–deficient mice. J Exp Med 188:1541–1546
79. Bot A, Bot S, Bona CA (1998) Protective role of gamma interferon during the recall response to influenza virus. J Virol 72:6637–6645
80. Weiss ID, Wald O, Wald H et al (2010) IFN-γ treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interf Cytokine Res 30:439–449. doi:10.1089/jir.2009.0084
81. Kim TS, Braciale TJ (2009) Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8 + T cell responses. PLoS One 4:e4204. doi:10.1371/journal.pone.0004204
82. GeurtsvanKessel CH, Willart MAM, van Rijt LS et al (2008) Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells. J Exp Med 205:1621–1634. doi:10.1084/jem.20071365
83. Heer AK, Harris NL, Kopf M, Marsland BJ (2008) CD4+ and CD8+ T cells exhibit differential requirements for CCR7-mediated antigen transport during influenza infection. J Immunol 181:6984–6994. doi:10.4049/jimmunol.181.10.6984
84. Duan S, Thomas PG (2016) Balancing immune protection and immune pathology by CD8+ T-cell responses to influenza infection. Immunol Mem 25. doi:10.3389/fimmu.2016.00025
85. Ramana CV, DeBerge MP, Kumar A et al (2015) Inflammatory impact of IFN-γ in CD8+ T cell-mediated lung injury is mediated by both Stat1-dependent and -independent pathways. Am J Physiol - Lung Cell Mol Physiol 308:L650–L657. doi:10.1152/ajplung.00360.2014
86. Wiley JA, Cerwenka A, Harkema JR et al (2001) Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol 158:119–130. doi:10.1016/S0002-9440(10)63950-8
87. Hamada H, de la Garcia-Hernandez ML, Reome JB et al (2009) Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182:3469–3481. doi:10.4049/jimmunol.0801814
88. Teijaro JR, Verhoeven D, Page CA et al (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84:9217–9226. doi:10.1128/JVI.01069-10
89. Teijaro JR, Turner D, Pham Q et al (2011) Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 187:5510–5514. doi:10.4049/jimmunol.1102243
90. + T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 122:2847–2856. doi:10.1172/JCI63689
91. Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–181. doi:10.1038/nri2711
92. Ouyang W, Rutz S, Crellin NK et al (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109. doi:10.1146/annurev-immunol-031210-101312
93. Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180:5771–5777. doi:10.4049/jimmunol.180.9.5771
94. McKinstry KK, Strutt TM, Buck A et al (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182:7353–7363. doi:10.4049/jimmunol.0900657
95. Sun J, Madan R, Karp CL, Braciale TJ (2009) Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 15:277–284. doi:10.1038/nm.1929
96. Sun K, Torres L, Metzger DW (2010) A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza a virus infection. J Virol 84:5007–5014. doi:10.1128/JVI.02408-09
97. Dutta A, Huang C-T, Chen T-C et al (2015) IL-10 inhibits neuraminidase-activated TGF-β and facilitates Th1 phenotype during early phase of infection. Nat Commun 6:6374. doi:10.1038/ncomms7374
98. de Jong MD, Simmons CP, Thanh TT et al (2006) Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203–1207. doi:10.1038/nm1477
99. Al HS et al (2009) Immunologic changes during pandemic (H1N1) China. Emerg Infect Dis J- CDC 17(6). doi:10.3201/eid1706.100643
100. Berasain C, Avila MA (2014) Amphiregulin. Semin Cell Dev Biol 28:31–41. doi:10.1016/j.semcdb.2014.01.005
101. Shoyab M, Plowman GD, McDonald VL et al (1989) Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 243:1074–1076. doi:10.1126/science.2466334
102. Zaiss DMW, Gause WC, Osborne LC, Artis D (2015) Emerging functions of Amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42:216–226. doi:10.1016/j.immuni.2015.01.020
103. Subramaniam R, Barnes PF, Fletcher K et al (2013) Protecting against post-influenza bacterial pneumonia by increasing phagocyte recruitment and ROS production. J Infect Dis. doi:10.1093/infdis/jit830
104. Hall OJ, Limjunyawong N, Vermillion MS et al (2016) Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females. PLoS Pathog 12:e1005840. doi:10.1371/journal.ppat.1005840
105. Kouro T, Takatsu K (2009) IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 21:1303–1309. doi:10.1093/intimm/dxp102
106. Nussbaum JC, Van Dyken SJ, von Moltke J et al (2013) Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502:245–248. doi:10.1038/nature12526
107. Mukherjee M, Sehmi R, Nair P (2014) Anti-IL5 therapy for asthma and beyond. World Allergy Organ J 7:32. doi:10.1186/1939-4551-7-32
108. Gorski SA, Hahn YS, Braciale TJ (2013) Group 2 innate lymphoid cell production of IL-5 is regulated by NKT cells during influenza virus infection. PLoS Pathog 9:e1003615. doi:10.1371/journal.ppat.1003615
109. Chang Y-J, Kim HY, Albacker LA et al (2011) Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 12:631–638. doi:10.1038/ni.2045
110. Graham MB, Braciale VL, Braciale TJ (1994) Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180:1273–1282. doi:10.1084/jem.180.4.1273
111. La Gruta NL, Kedzierska K, Stambas J, Doherty PC (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85:85–92. doi:10.1038/sj.icb.7100026
112. Samarasinghe AE, Woolard SN, Boyd KL et al (2014) The immune profile associated with acute allergic asthma accelerates clearance of influenza virus. Immunol Cell Biol 92:449–459. doi:10.1038/icb.2013.113
113. Samarasinghe AE, Melo RCN, Duan S et al (2017) Eosinophils promote antiviral immunity in mice infected with influenza a virus. J Immunol:1600787. doi:10.4049/jimmunol.1600787
114. Oldstone MBA, Teijaro JR, Walsh KB, Rosen H (2013) Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology 435:92–101. doi:10.1016/j.virol.2012.09.039
115. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H (2014) S1P signaling: new therapies and opportunities. F1000Prime Rep. doi:10.12703/P6-109
116. Chang DH, Bednarczyk RA, Becker ER et al (2016) Trends in U.S. hospitalizations and inpatient deaths from pneumonia and influenza, 1996–2011. Vaccine 34:486–494. doi:10.1016/j.vaccine.2015.12.003